No Data
US Stock MarketDetailed Quotes
AGIO Agios Pharmaceuticals
Watchlist
24.330
-0.200-0.82% Trading 09/25 14:59 ET
24.790High24.060Low130.92KVolume
24.470Open24.530Pre Close3.21MTurnover0.25%Turnover RatioLossP/E (TTM)1.36BMarket Cap31.87052wk HighLossP/E (Static)55.74MShares21.07052wk Low1.41P/B1.26BFloat Cap138.850Historical High--Dividend TTM51.68MShs Float15.770Historical Low--Div YieldTTM2.98%Amplitude24.526Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Agios Pharmaceuticals Company
Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Revenue Breakdown
Business
Unit:USD
12/31/2022
Stock NameRevenueRatio
Product revenue, net11.74M82.44%
Milestone revenue2.5M17.56%
News
Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 45%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Agios Pharmaceuticals fair value estimate is US$44.45 Current share price of US$24.53 suggests Agios Pharmaceuticals is potentially 45% under
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is
Express News | Agios Pharmaceuticals Price Target Cut to $32.00/Share From $33.00 by JP Morgan
Comments
ColumnsToday's Pre-Market Stock Movers: TTWO, AZO, BLUE, PRPL and More
Gapping up
In reaction to earnings/guidance:
• $AutoZone(AZO.US$ +2.7%,$Jacobs Engineering(J.US$ +0.9% (reaffirms Q4 EPS and adjusted EBITDA guidance)
Other news:
• $Purple Innovation(PRPL.US$ +32.6% (confirms it received an unsolicited, non-binding proposal from Coliseum Capital Management to acquire all of the outstanding capital stock of Purple for $4.35 per share)
• $KnowBe4(KNBE.US$ +24.9% (received a non-binding proposal f...
In reaction to earnings/guidance:
• $AutoZone(AZO.US$ +2.7%,$Jacobs Engineering(J.US$ +0.9% (reaffirms Q4 EPS and adjusted EBITDA guidance)
Other news:
• $Purple Innovation(PRPL.US$ +32.6% (confirms it received an unsolicited, non-binding proposal from Coliseum Capital Management to acquire all of the outstanding capital stock of Purple for $4.35 per share)
• $KnowBe4(KNBE.US$ +24.9% (received a non-binding proposal f...
15
3
ColumnsToday's Pre-Market Stock Movers: FL, DE, BBBY, AMC and More
Gainers:
In reaction to earnings/guidance:
• $Foot Locker(FL.US$ +19.7%,$BILL Holdings(BILL.US$ +18.1% (also names new COO),$Buckle Inc(BKE.US$ +1.7%
Other news:
• $Axsome Therapeutics(AXSM.US$ +33.8% (announces FDA approval of AUVELITY the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults)
• $SpringWorks Therapeutics(SWTX.US$ +4.9% (late-breaking oral presentation of phase 3 DeFi da...
In reaction to earnings/guidance:
• $Foot Locker(FL.US$ +19.7%,$BILL Holdings(BILL.US$ +18.1% (also names new COO),$Buckle Inc(BKE.US$ +1.7%
Other news:
• $Axsome Therapeutics(AXSM.US$ +33.8% (announces FDA approval of AUVELITY the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults)
• $SpringWorks Therapeutics(SWTX.US$ +4.9% (late-breaking oral presentation of phase 3 DeFi da...
13
1
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
oachkatzl : TTWO..... IV = 4, VI = 6
Moomoo Breakfast USOP oachkatzl: Trade safe!
Alexwu5 :